PD-L1 – inhibitors in neuroendocrine neoplasia: Results from a real-life study

Immune check-point inhibitors (ICIs) have changed our view on how to treat cancer. Despite their approval in treatment of many different cancers, efficacy of immune check-point inhibitors (ICI) in neuroendocrine neoplasia is limited and poorly understood. Established treatment options of neuroendocr...

Descripción completa

Detalles Bibliográficos
Autores principales: Özdirik, Burcin, Jann, Henning, Bischoff, Philip, Fehrenbach, Uli, Tacke, Frank, Roderburg, Christoph, Wiedenmann, Bertram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793325/
https://www.ncbi.nlm.nih.gov/pubmed/33429744
http://dx.doi.org/10.1097/MD.0000000000023835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793325/
https://www.ncbi.nlm.nih.gov/pubmed/33429744
http://dx.doi.org/10.1097/MD.0000000000023835

Ejemplares similares